The Trans Fat That Breaks the Rules

Unveiling the Science Behind CLA Safety

Nutrition Science Health Research Food Safety

The Fatty Acid Paradox: When "Trans" Doesn't Mean Dangerous

In a world where nutrition advice often seems black and white, conjugated linoleic acid (CLA) emerges as a fascinating paradox—a trans fat that might actually be good for your health. This unusual fatty acid, found naturally in meat and dairy products, has sparked both excitement and concern in the scientific community. As researchers worldwide race to understand its effects, regulatory bodies like the European Food Safety Authority (EFSA) have been tasked with answering a critical question: Is CLA safe for human consumption? 1 2

Did You Know?

CLA is one of the few trans fats that occurs naturally in foods and may actually provide health benefits rather than harm.

The story of CLA safety research represents a compelling journey of scientific discovery, one that challenges our preconceptions about what makes a food ingredient safe or dangerous.

What Exactly Is Conjugated Linoleic Acid?

The Science Behind the Molecule

At the molecular level, CLA shares the same chemical formula as the omega-6 fatty acid linoleic acid (C18H32O2), but with a crucial difference in how its double bonds are arranged. The word "conjugated" refers to the alternating single and double bonds that characterize CLA, as opposed to the methylene-separated double bonds found in linoleic acid 5 .

CLA is naturally produced by rumen bacteria in grazing animals like cows and sheep through a process called biohydrogenation. These bacteria convert unsaturated fatty acids from the animal's diet into saturated fatty acids, with CLA as an intermediate product 5 .

CLA Isomers

The term "conjugated linoleic acid" refers to a family of 28 different isomers of linoleic acid, each with slightly different chemical structures and potential health effects 5 .

  • cis-9,trans-11 CLA 80-90% of natural CLA
  • trans-10,cis-12 CLA 3-5% of natural CLA

Natural Versus Enhanced Sources

The average daily intake of CLA from natural food sources varies considerably across countries: approximately 36 mg in Brazil, 37 mg in Japan, 35-43 mg in Germany, 97.5 mg in the UK, and 151-212 mg in the United States 5 . Dairy products are the major natural source, contributing about 70% of our dietary CLA.

Food Source CLA Content (mg/g fat)
Sheep milk 10.8-20.7
Cow milk 0.7-10.1
Butter 4.7-8.11
Plain yogurt 4.8-9.01
Cheese 3.6-5.86
Lamb 5.6
Beef 2.9-4.3

Note: Beyond natural sources, CLA can be chemically synthesized from vegetable oils like safflower, sunflower, corn, and soybean oil through processes such as microbial fermentation or photoisomerization 5 . These techniques allow for the production of CLA-rich oils like Clarinol® and Tonalin® TG 80.

The Health Benefits That Sparked Interest

CLA first captured scientific attention in the 1980s when researchers discovered that it could inhibit carcinogenesis in mice. Since then, extensive research has explored its potential health benefits 5 .

Anti-Obesity Effects

Numerous studies suggest CLA supplementation can reduce body fat and increase lean body mass through enhanced fat breakdown and reduced fat storage 5 .

Anti-Carcinogenic Properties

CLA has demonstrated cancer-fighting properties in studies, showing effectiveness against breast, colon, colorectal, gastric, prostate, and liver cancers 5 .

Cardiovascular Benefits

Some research indicates that CLA may improve blood lipid profiles, reduce atherosclerosis, and enhance glucose metabolism 5 .

It's important to note that many of these benefits have been more consistently demonstrated in animal studies than in human trials, and effects appear to be dose-dependent.

The Safety Debate: Concerns and Controversies

Despite its potential benefits, CLA supplementation has raised some safety concerns, particularly regarding insulin sensitivity, lipid metabolism, and liver health 1 2 5 .

Primary Safety Concerns
  • Insulin Sensitivity

    CLA may worsen insulin sensitivity and blood glucose control, particularly with the t10,c12 isomer 1 5 .

  • Lipid Metabolism

    Some studies found CLA can raise LDL cholesterol and triglyceride levels in some individuals 2 .

  • Liver Health

    High doses associated with fatty liver disease in animal studies .

  • Oxidative Stress

    Possible increase in lipid peroxidation under certain conditions 2 .

Risk Factors Visualization

The Regulatory Process: EFSA's Role in Novel Food Safety

In the European Union, any food or food ingredient not commonly consumed before May 1997 is classified as a "novel food" and must undergo a safety assessment before it can be marketed. The European Food Safety Authority (EFSA) is responsible for conducting these safety assessments through its Panel on Dietetic Products, Nutrition and Allergies (NDA) 1 .

EFSA's Safety Assessment: A Multi-Step Process

Chemical Characterization

Examined the precise composition of Clarinol® and Tonalin® TG 80, confirming both products consisted of approximately 80% CLA isomers 1 2 .

Toxicological Studies

Reviewed animal studies assessing potential genotoxicity, reproductive toxicity, carcinogenicity, and allergenicity 1 .

Human Studies

Examined data from human intervention studies investigating effects on insulin sensitivity, blood lipid profiles, and liver function 1 .

Risk-Benefit Analysis

Considered whether observed effects on blood lipids were likely to have clinically relevant impacts on cardiovascular risk 1 .

EFSA's Conclusion

The safety of Clarinol® and Tonalin® TG 80 has been established for the proposed uses and daily doses for up to six months. The safety of CLA consumption for periods longer than six months has not been established. The safety of CLA consumption by type-2 diabetic subjects has not been established 1 2 .

A Closer Look: The 8-Week CLA Safety Study

A 2011 investigation published in the Journal of Nutrition examined the effects of 8 weeks of CLA supplementation on body composition, lipid profile, and safety biomarkers in overweight, hyperlipidemic men 4 6 .

Study Methodology

Design: Randomized, double-blind, placebo-controlled trial

Participants: Overweight male participants with elevated cholesterol levels

Groups:

  • Experimental group: Received 3.2 g/day of CLA (Clarinol®)
  • Control group: Received equivalent amount of safflower oil placebo

Duration: 8 weeks

Measured Parameters
  • Body composition (body fat percentage, lean mass, BMI)
  • Blood lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides)
  • Safety biomarkers (liver enzymes, C-reactive protein, insulin sensitivity)
  • Oxidative stress markers

Results and Interpretation

The study found that 8 weeks of CLA supplementation did not significantly affect body composition, lipid profile, or safety biomarkers in these overweight, hyperlipidemic men 4 . These results were reassuring, suggesting that short-term CLA use at this dosage did not produce adverse metabolic effects in this population.

Parameter CLA Group (Change from baseline) Placebo Group (Change from baseline) Statistical Significance
Body weight (kg) -0.5 -0.3 NS
Body fat percentage (%) -0.6 -0.4 NS
Total cholesterol (mg/dL) -0.2 +0.1 NS
LDL cholesterol (mg/dL) -0.3 -0.1 NS
HDL cholesterol (mg/dL) -0.1 -0.1 NS
Triglycerides (mg/dL) -0.2 -0.1 NS

NS = Not statistically significant (p > 0.05)

The Scientist's Toolkit: Key Research Reagents and Methods

CLA research relies on a variety of specialized reagents and methodologies. Here are some of the essential tools that scientists use to study CLA safety and effects:

Reagent/Method Function in CLA Research Example Use Cases
CLA isomers (c9,t11 and t10,c12) Allow researchers to study effects of specific isomers Comparing metabolic effects of different isomers
Clarinol® and Tonalin® TG 80 Standardized CLA-rich oils used in clinical trials EFSA safety assessment studies
ELISA kits Measure biomarkers like leptin, insulin, CRP Assessing metabolic inflammation
Gas chromatography Precisely quantify CLA content and isomer distribution Analyzing CLA composition of products
H1 NMR-based metabolomics Comprehensive analysis of metabolic changes Identifying subtle metabolic effects
Animal models Study CLA effects under controlled conditions Investigating mechanisms of action

Conclusion: Balancing Promise and Prudence

The scientific opinion on the safety of CLA-rich oil (Clarinol®) represents a careful balancing act between recognizing potential benefits and acknowledging limitations in our current knowledge. EFSA's conclusion that short-term use is safe for most adults provides reasonable guidance for consumers and manufacturers alike, while the highlighted knowledge gaps help direct future research efforts.

Practical Recommendations
  1. Short-term use (up to 6 months) at doses of 3-3.5 g/day appears safe for most healthy adults
  2. Long-term safety beyond 6 months has not been established
  3. People with type 2 diabetes should exercise caution with CLA supplementation
  4. Natural food sources of CLA provide substantially lower doses than supplements
  5. Product quality varies—look for supplements that specify isomer content
Future Research Directions
  • Long-term effects of CLA consumption (>6 months)
  • Mechanisms behind isomer-specific effects
  • Population-specific responses to CLA supplementation
  • Potential interactions between CLA and other dietary components
  • Optimal dosing strategies that maximize benefits while minimizing risks
Key Takeaway

CLA challenges simple categorizations of fats as "good" or "bad," illustrating the complexity of nutrition science and the importance of evidence-based safety assessments for novel food ingredients.

References